This undated picture shows a laboratory at the U.S. biotech company Avigen, where new treatment options based on gene transfer like drugs for hemophilia B are developed. (Associated Press/Bayer AG) **FILE**
Featured Photo Galleries
This undated picture shows a laboratory at the U.S. biotech company Avigen, where new treatment options based on gene transfer like drugs for hemophilia B are developed. (Associated Press/Bayer AG) **FILE**
